- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02077894
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing. This includes identifying mutations in known genes or novel genes for recognized conditions, as well as identifying mutations in novel genes for previously uncharacterized genetic conditions involving the eye.
Study Population: We plan to recruit 1,685 participants, to include both participants with an eye condition under study and unaffected family members. Ideally unaffected family members will be parents of an affected participant.
Design: Most affected participants will be recruited from existing studies at the NEI. These include, but are not limited to, the Screening Protocol (08-EI-0102), the NEI Ocular Natural History protocol (16-EI-0134), the Genetics of Inherited Eye Disease protocol (15-EI-0128) and the Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC) study (13-EI-0049). Unaffected family members will be invited to participate once an affected relative is determined eligible for participation. Offsite affected and unaffected participants will also be enrolled. If a participant is self-referred or referred to the study by an outside provider, screening will determine whether participation is offered.
Offsite participants will be screened via phone or secure videoconference, and records will be requested for evaluation of affected participants.. Both affected and unaffected eligible participants will undergo genetic counseling and will provide a blood sample and/or saliva sample for exome or genome sequencing. Biological relationships may be confirmed prior to exome or genome sequencing. Sequence data will be analyzed for primary variants and secondary findings, unless participants choose to opt-out of secondary analysis and reporting. All sequence variants deemed clinically relevant will be validated in a CLIA-certified laboratory and the results will be returned to the participant in-person, secure video conference, or by telephone.
Outcome Measures: This is an etiologic study that will generate molecular information about previously-recognized conditions for which participants did not have a molecular diagnosis, as well as molecular information for previously uncharacterized conditions involving the eye.
Study Overview
Status
Conditions
Detailed Description
Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing (referred to as exome sequencing and genome sequencing in the remainder of the document). This includes identifying mutations in known genes or novel genes for recognized conditions, as well as identifying mutations in novel genes for previously uncharacterized genetic conditions involving the eye.
Study Population: We plan to recruit 1,685 participants, to include both participants with an eye condition under study and unaffected family members. Ideally unaffected family members will be parents of an affected participant.
Design: Participants will be self-referred or referred by an outside clinician. They will preferably be evaluated at the NIH, but the option to participate offsite will be offered. Participants evaluated onsite will be recruited through other pre-existing NIH protocols, such as the NEI Screening protocol (08-EI-0102), the NEI Ocular Natural History protocol (16-EI-0134), the Genetics of Inherited Eye Disease protocol (15-EI-0128), and the Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC) protocol (13-EI-0049).
Offsite participants will be screened via phone or secure videoconference, and records will be requested for evaluation of affected participants.. Both affected and unaffected eligible participants will undergo genetic counseling and will provide a blood sample and/or saliva sample for exome or genome sequencing. Biological relationships will be confirmed prior to exome or genome sequencing. Sequence data will be analyzed for primary variants and secondary findings, unless participants choose to opt-out of secondary analysis and reporting. All sequence variants deemed clinically relevant will be validated in a CLIA-certified laboratory and the results will be returnedto the participant in-person, secure videoconference, or by telephone.
Outcome Measures: This is an etiologic study that will generate molecular information about previously-recognized conditions for which participants did not have a molecular diagnosis, as well as molecular information for previously uncharacterized conditions involving the eye.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Bin Guan, Ph.D.
- Phone Number: (301) 594-0029
- Email: bin.guan@nih.gov
Study Contact Backup
- Name: Delphine Blain, M.D.
- Phone Number: (301) 496-1410
- Email: delphine.blan@nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center,
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY dial 711 800-411-1222
- Email: ccopr@nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
INCLUSION CRITERIA
- Participant is affected with an eye condition under study, or is a family member of an affected individual who will be informative for ES/GS analysis and interpretation.
- Participant or legal guardian of participant understands and signs the informed consent document.
EXCLUSION CRITERIA
- Participants who cannot comply with study procedures are ineligible.
- Participants who are minors or participants who are adults and are decisionally impaired are ineligible if they do not have a legal guardian who can consent and make decisions on their behalf. Documentation of legal guardianship must be provided for decisionally impaired adults.
- Participants who are minors and under joint custody are ineligible if parents are in disagreement about study participation.
- Prospective participants or their legal guardians who, based on the judgment of the team, appear to have impaired ability to understand and appropriately use complex medical and genetic information, or to cope with potentially life altering medical information, will be ineligible.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Affected participants
Participants with an eye disease.
|
Unaffected family members
Unaffected family members.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
This is an etiologic study that will generate new genes or variants for inherited eye diseases.
Time Frame: Until the affected participant has received confirmed Primary Results (PRs). Unaffected family members may or may not receive any results, but their participation will be ongoing until their affected family member receives PRs.
|
This is an etiologic study that will generate molecular information about previously-recognized conditions for which participants did not have a molecular diagnosis, as well as molecular information for previously uncharacterized eye conditions.
|
Until the affected participant has received confirmed Primary Results (PRs). Unaffected family members may or may not receive any results, but their participation will be ongoing until their affected family member receives PRs.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bin Guan, Ph.D., National Eye Institute (NEI)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 140064
- 14-EI-0064
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Eye Disease
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)CompletedHereditary Eye DiseaseUnited States
-
National Eye Institute (NEI)Completed
-
The Hospital for Sick ChildrenRecruitingGenetic Disease | Inherited DiseaseCanada
-
Hospital de Olhos Sadalla Amin GhanemCompletedEye Diseases, Hereditary
-
Catholic University of the Sacred HeartUnknownRetinal Degeneration | Genetic Disease | Single-Gene Defects | Macular DystrophyItaly
-
Seoul National University HospitalCompletedEye Diseases | Retinal Degeneration | Retinal Diseases | Retinitis Pigmentosa | Eye Disease, HereditaryKorea, Republic of
-
Shanghai High Myopia Study GroupEye & ENT Hospital of Fudan UniversityRecruiting
-
University Hospital, Strasbourg, FranceTerminatedToxoplasmosis Infection | Genotype II | Ocular Toxoplasmosis With RecurrencesFrance
-
Evidence Based Cataract Study GroupEye & ENT Hospital of Fudan UniversityRecruitingVisual Outcome | Congenital Cataract | Traumatic Cataract | Pediatric Cataract | Genetic AnticipationChina